BioCryst Pharmaceuticals, Inc. (BCRX) Lifted to “Sell” at BidaskClub
BidaskClub upgraded shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) from a strong sell rating to a sell rating in a research note issued to investors on Friday morning.
Several other research firms have also recently weighed in on BCRX. Zacks Investment Research cut BioCryst Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, May 2nd. Needham & Company LLC reiterated a hold rating on shares of BioCryst Pharmaceuticals in a report on Friday, May 19th. Noble Financial reiterated a buy rating on shares of BioCryst Pharmaceuticals in a report on Sunday, May 28th. ValuEngine cut BioCryst Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, August 10th. Finally, HC Wainwright reissued a buy rating on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 8th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $8.00.
Shares of BioCryst Pharmaceuticals (BCRX) opened at 4.58 on Friday. BioCryst Pharmaceuticals has a 52-week low of $3.75 and a 52-week high of $9.25. The firm’s market capitalization is $368.36 million. The company has a 50 day moving average of $4.97 and a 200 day moving average of $6.16.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.02. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $5.79 million. During the same quarter last year, the firm earned ($0.22) EPS. The company’s revenue for the quarter was down 35.4% on a year-over-year basis. On average, analysts anticipate that BioCryst Pharmaceuticals will post ($0.74) earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of BCRX. UBS Asset Management Americas Inc. bought a new position in BioCryst Pharmaceuticals during the first quarter valued at $392,000. Swiss National Bank raised its position in BioCryst Pharmaceuticals by 18.7% in the first quarter. Swiss National Bank now owns 114,300 shares of the biotechnology company’s stock valued at $960,000 after buying an additional 18,000 shares during the period. Bank of New York Mellon Corp raised its position in BioCryst Pharmaceuticals by 6.8% in the first quarter. Bank of New York Mellon Corp now owns 361,289 shares of the biotechnology company’s stock valued at $3,035,000 after buying an additional 23,072 shares during the period. Emory University bought a new position in BioCryst Pharmaceuticals during the first quarter valued at $3,153,000. Finally, Trexquant Investment LP raised its position in BioCryst Pharmaceuticals by 39.3% in the first quarter. Trexquant Investment LP now owns 50,791 shares of the biotechnology company’s stock valued at $427,000 after buying an additional 14,333 shares during the period. 86.23% of the stock is currently owned by hedge funds and other institutional investors.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Receive News & Stock Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.